Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

The latest 13F from Great Point Partners LLC covers Q2 2026 (filed Aug 14, 2026): 37 long positions worth $424.4M. The top 10 holdings make up 53.6% of the portfolio, and the largest is Vor Biopharma Inc. (VOR) at 7.4%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$94.6M
Added
7
Est. +$48.7M
Reduced
9
Est. −$58.8M
Sold out
12
Est. −$111.9M

Top 5 holdings

Share of this quarter's portfolio value

  1. VORVor Biopharma Inc.
    7.4%$31.3MHistory
  2. ABVXAbivax S.A.
    6.4%$27.2MHistory
  3. VERAVera Therapeutics, Inc.
    6.1%$25.8MHistory
  4. ZURAZura Bio Ltd
    5.9%$24.9MHistory
  5. ALMSAlumis Inc.
    5.7%$24.1MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. ABVXAbivax S.A.
    +$27.2MNewHistory
  2. DFTXDefinium Therapeutics, Inc.
    +$20.0MNewHistory
  3. VERAVera Therapeutics, Inc.
    +$17.2MAddedHistory
  4. SGMTSagimet Biosciences Inc.
    +$15.7MNewHistory
  5. IMMXImmix Biopharma, Inc.
    +$9.56MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ABVXAbivax S.A.
    +6.41 pp0.0% → 6.4%History
  2. DFTXDefinium Therapeutics, Inc.
    +4.71 pp0.0% → 4.7%History
  3. VERAVera Therapeutics, Inc.
    +4.11 pp2.0% → 6.1%History
  4. SGMTSagimet Biosciences Inc.
    +3.70 pp0.0% → 3.7%History
  5. IMMXImmix Biopharma, Inc.
    +2.32 pp0.8% → 3.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. APGEApogee Therapeutics, Inc.
    −$31.5MSold outHistory
  2. AMLXAmylyx Pharmaceuticals, Inc.
    −$18.9MReducedHistory
  3. KALVKalVista Pharmaceuticals, Inc.
    −$13.6MSold outHistory
  4. IMVTImmunovant, Inc.
    −$13.6MSold outHistory
  5. JBIOJade Biosciences, Inc.
    −$13.6MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. APGEApogee Therapeutics, Inc.
    −7.71 pp7.7% → 0.0%History
  2. KALVKalVista Pharmaceuticals, Inc.
    −3.33 pp3.3% → 0.0%History
  3. IMVTImmunovant, Inc.
    −3.32 pp3.3% → 0.0%History
  4. JBIOJade Biosciences, Inc.
    −3.32 pp3.3% → 0.0%History
  5. AMLXAmylyx Pharmaceuticals, Inc.
    −3.00 pp6.0% → 3.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$424.4M
+$16.2M (+4.0%) vs. prior quarter
Positions
37
−2 vs. prior quarter
Top 10 concentration
53.6%
Top 10 as share of value
Turnover
34.4%
Q2 2026, one quarter
Average holding period
3.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $641.6M (Q1 2024)

Q1 2021: $483.9MQ2 2021: $447.2MQ3 2021: $422.9MQ4 2021: $447.4MQ1 2022: $413.2MQ2 2022: $388.1MQ3 2022: $415.3MQ4 2022: $483.7MQ1 2023: $506.0MQ2 2023: $499.2MQ3 2023: $531.6MQ4 2023: $586.7MQ1 2024: $641.6MQ2 2024: $522.0MQ3 2024: $331.4MQ4 2024: $212.2MQ1 2025: $184.0MQ2 2025: $153.8MQ3 2025: $239.5MQ4 2025: $308.4MQ1 2026: $408.3MQ2 2026: $424.4M
Q1 2021Q2 2026
13F filings of Great Point Partners LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202637$424.4MVORABVXVERAvs. Q1 2026SEC
Q1 2026May 15, 202639$408.3MAPGEVORZURAvs. Q4 2025SEC
Q4 2025Feb 17, 202629$308.4MAPGEAMLXZURAvs. Q3 2025SEC
Q3 2025Nov 14, 202528$239.5MAMLXRZLTNKTRvs. Q2 2025SEC
Q2 2025Aug 14, 202526$153.8MIONSRZLTAMLXvs. Q1 2025SEC
Q1 2025May 15, 202531$184.0MCYTKKALVEOLSvs. Q4 2024SEC
Q4 2024Feb 14, 202526$212.2MIONSCYTKKALVvs. Q3 2024SEC
Q3 2024Nov 13, 202429$331.4MNGNEABVXPLRXvs. Q2 2024SEC
Q2 2024Aug 14, 202433$522.0MURGNNGNEABVXvs. Q1 2024SEC
Q1 2024May 15, 202435$641.6MNGNEALPNURGNvs. Q4 2023SEC
Q4 2023Feb 14, 202434$586.7MALPNCYTKURGNvs. Q3 2023SEC
Q3 2023Nov 14, 202339$531.6MURGNALPNPLRXvs. Q2 2023SEC
Q2 2023Aug 14, 202336$499.2MALPNRAREPCVXvs. Q1 2023SEC
Q1 2023May 15, 202342$506.0MPLRXXENEALPNvs. Q4 2022SEC
Q4 2022Feb 14, 202340$483.7MPCVXXENERAPTvs. Q3 2022SEC
Q3 2022Nov 14, 202240$415.3MXENEJAZZPNTvs. Q2 2022SEC
Q2 2022Aug 15, 202233$388.1MXENEJAZZCYTKvs. Q1 2022SEC
Q1 2022May 16, 202229$413.2MEXELXENETVTXvs. Q4 2021SEC
Q4 2021Feb 14, 202235$447.4MARNAEXELXENEvs. Q3 2021SEC
Q3 2021Nov 15, 202135$422.9MEXELARNAKDMNvs. Q2 2021SEC
Q2 2021Aug 16, 202128$447.2MMGNXRCKTARNAvs. Q1 2021SEC
Q1 2021May 17, 202128$483.9MMGNXRCKTIOVA–SEC

13D and 13G filings

Companies where Great Point Partners LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

7 companies, largest stake first.

Companies where Great Point Partners LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
SCYXScynexis Inc13G/A9.99%4.08M shares0.00 ppfrom 9.99%Apr 7, 20262 filingsAug 14, 2026SEC
SLGLSol-Gel Technologies Ltd.13G8.45%274.4K sharesNewMar 31, 20261 filingMar 31, 2026SEC
PMNProMIS Neurosciences Inc.13G/A7.66%736.9K shares−2.33 ppfrom 9.99%Aug 5, 20248 filingsAug 14, 2026SEC
AMANAmanat Acquisition Corp.13G/A6.67%500.0K shares+1.50 ppfrom 5.17%May 27, 20262 filingsAug 14, 2026SEC
RACCResearch Alliance Corp III13G6.49%504.9K sharesNewSep 11, 20261 filingSep 11, 2026SEC
JATTJATT II Acquisition Corp.13G/A6.23%500.0K shares−0.18 ppfrom 6.41%Apr 24, 20262 filingsAug 14, 2026SEC
JTTTJATT III Acquisition Corp13G5.83%450.0K sharesNewSep 2, 20261 filingSep 2, 2026SEC

Latest filings

98 filings on file made by Great Point Partners LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Great Point Partners LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
RACCResearch Alliance Corp IIISep 11, 20264:00 PM ET13G6.49%504.9K sharesNewSep 4, 2026SEC
JTTTJATT III Acquisition CorpSep 2, 20264:03 PM ET13G5.83%450.0K sharesNewAug 26, 2026SEC
PMNProMIS Neurosciences Inc.Aug 14, 20269:35 AM ET13G/A7.66%736.9K shares−2.33 ppfrom 9.99%Jun 30, 2026SEC
JATTJATT II Acquisition Corp.Aug 14, 20269:34 AM ET13G/A6.23%500.0K shares−0.18 ppfrom 6.41%Jun 30, 2026SEC
SCYXScynexis IncAug 14, 20269:33 AM ET13G/A9.99%4.08M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
AMANAmanat Acquisition Corp.Aug 14, 20269:32 AM ET13G/A6.67%500.0K shares+1.50 ppfrom 5.17%Jun 30, 2026SEC
AMANAmanat Acquisition Corp.May 27, 20264:00 PM ET13G5.17%500.0K sharesNewMay 19, 2026SEC
PMNProMIS Neurosciences Inc.May 15, 20268:55 AM ET13G9.99%954.1K shares0.00 ppfrom 9.99%Mar 31, 2026SEC
CNTXContext Therapeutics Inc.May 15, 20268:55 AM ET13G/A2.44%2.24M shares−2.66 ppfrom 5.10%Below 5%Mar 31, 2026SEC
ZURAZura Bio LtdMay 15, 20268:54 AM ET13G/A4.44%4.22M shares−0.74 ppfrom 5.18%Below 5%Mar 31, 2026SEC
JATTJATT II Acquisition Corp.Apr 24, 20264:21 PM ET13G6.41%500.0K sharesNewApr 17, 2026SEC
SCYXScynexis IncApr 7, 20264:00 PM ET13G9.99%7.98M sharesNewMar 31, 2026SEC
SLGLSol-Gel Technologies Ltd.Mar 31, 20266:03 PM ET13G8.45%274.4K sharesNewMar 24, 2026SEC
PMNProMIS Neurosciences Inc.Feb 17, 20264:24 PM ET13G/A9.99%409.6K shares0.00 ppfrom 9.99%Dec 31, 2025SEC
CNTXContext Therapeutics Inc.Feb 17, 20264:17 PM ET13G/A5.10%4.68M shares−0.12 ppfrom 5.22%Dec 31, 2025SEC
IVAInventiva S.A.Feb 17, 20264:17 PM ET13G/A3.49%6.78M shares−2.57 ppfrom 6.06%Below 5%Dec 31, 2025SEC
VTGNVistagen Therapeutics, Inc.Feb 17, 20264:16 PM ET13G/A4.95%2.06M shares−1.33 ppfrom 6.28%Below 5%Dec 31, 2025SEC
ZURAZura Bio LtdFeb 17, 20264:15 PM ET13G/A5.18%3.82M shares−0.69 ppfrom 5.87%Dec 31, 2025SEC
VORVor Biopharma Inc.Feb 17, 20264:13 PM ET13G/A3.30%1.37M shares−2.33 ppfrom 5.63%Below 5%Dec 31, 2025SEC
VORVor Biopharma Inc.Dec 17, 20254:00 PM ET13G5.63%1.23M sharesNewDec 10, 2025SEC